The Journal of Thoracic and Cardiovascular Surgery
Volume 131, Issue 3 , Pages 533-539 , March 2006

A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study

Received 17 June 2005 ,Revised 6 October 2005 ,Accepted 20 October 2005.

References 

  1. Hirsh J . Heparin . N Engl J Med. . 1991;324:1565–1574
  2. Ranucci M , Frigiola A , Menicanti L , Ditta A , Boncilli A , Brozzi S . Postoperative antithrombin levels and outcome in cardiac operations . Crit Care Med. . 2005;33:355–360
  3. Warkentin TE , Greinacher A . Heparin-induced thrombocytopenia and cardiac surgery . Ann Thorac Surg. . 2003;76:2121–2131
  4. Hirsh J , Anand SS , Halperin JL , Fuster V  American Heart Association . Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association . Circulation . 2001;103:2994–3018
  5. Patella V , Ciccarelli A , Lamparter-Schummert B , de Paulis A , Adt M , Marone G . Heterogeneous effects of protamine on human mast cells and basophils . Br J Anaesth. . 1997;78:724–730
  6. Park KW . Protamine and protamine reactions . Int Anesthesiol Clin. . 2004;42:135–145
  7. Welsby IJ , Newman MF , Phillips-Bute B , Messier RH , Kakkis ED , Stafford-Smith M . Hemodynamic changes after protamine administration (association with mortality after coronary artery bypass surgery) . Anesthesiology . 2005;102:308–314
  8. Kimmel SE , Sekeres M , Berlin JA , Ellison N . Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass . Anesth Analg. . 2002;94:1402–1408
  9. Bittl JA , Chaitman B , Feit F , Kimball W , Topol EJ . Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina (final report reanalysis of the Bivalirudin Angioplasty Study) . Am Heart J. . 2001;142:952–959
  10. Lincoff AM , Bittl JA , Kleiman NS , Sarembock IJ , Jackman JD , Mehta S , et al.   Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI linking Angiomax to Reduced Clinical Events REPLACE-1 trial) . Am J Cardiol . 2004;93:1092–1096
  11. Lincoff AM , Kleiman NS , Kereiakes DJ , Feit F , Bittl JA , Jackman JD , et al.   Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization (REPLACE-2 Randomized Trial) . JAMA . 2004;292:696–703
  12. Merry AF , Raudkivi PJ , Middleton NG , McDougall JM , Nand P , Mills BP , et al.   Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery . Ann Thorac Surg. . 2004;77:925–931
  13. Koster A , Spiess B , Chew DP , Krabatsch T , Tambeur L , DeAnda A , et al.   Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting . Am J Cardiol. . 2004;93:356–359
  14. Weitz JI , Bates ER . Direct thrombin inhibitors in cardiac disease . Cardiovasc Toxicol. . 2003;3:13–25
  15. Robson R , White H , Aylward P , Frampton C . Bivalirudin pharmacokinetics and pharmacodynamics (effect of renal function, dose, and gender) . Clin Pharmacol Ther. . 2002;71:433–439
  16. Ramsay J , Shernan S , Fitch J , Finnegan P , Todaro T , Filloon T , et al.   Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves . J Thorac Cardiovasc Surg. . 2005;129:300–306
  17. Thielmann M , Massoudy P , Marggraf G , Knipp S , Schmermund A , Piotrowski J , et al.   Role of troponin I, myoglobin, and creatine kinase for the detection of early graft failure following coronary artery bypass grafting . Eur J Cardiothorac Surg. . 2004;26:102–109
  18. Xiao Z , Theroux P . Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor . Circulation . 1998;97:251–256
  19. Sobel M , Fish WR , Toma N , Luo S , Bird K , Mori K , et al.   Heparin modulates integrin function in human platelets . J Vasc Surg. . 2001;33:587–594
  20. Avidan MS , Levy JH , Scholz J , Delphin E , Rosseel PM , Howie MB , et al.   Phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass . Anesthesiology . 2005;102:276–284
  21. Frankel TL , Stamou SC , Lowery RC , Kapetanakis EI , Hill PC , Haile E , et al.   Risk factors for hemorrhage-related reexploration and blood transfusion after conventional versus coronary revascularization without cardiopulmonary bypass . Eur J Cardiothorac Surg. . 2005;27:494–500
  22. Stover EP , Siegel LC , Parks R , Levin J , Body SC , Maddi R , et al.   Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines (a 24 institution study) . Anesthesiology . 1998;88:327–333
  23. Spiess BD , Royster D , Levy JH , Fitch J , Dietrich W , Body S , et al.   Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes . Transfusion . 2004;44:1143–1148

 Funding for this study came from The Medicines Company, Parsippany, New Jersey. Authors had complete access to all data and sole authority over the final decision for publication. The following authors disclose part-time consulting arrangements with The Medicines Company: Cornelius McKown Dyke, Andreas Koster, Bruce D. Speiss, and Harry L. McCarthy, II. Solomon Aronson had a full-time consulting arrangement with The Medicines Company. No author has significant equity interests or patent-licensing arrangements with The Medicines Company.

PII: S0022-5223(05)01916-1

doi: 10.1016/j.jtcvs.2005.09.057

The Journal of Thoracic and Cardiovascular Surgery
Volume 131, Issue 3 , Pages 533-539 , March 2006

Article Tools

* Image Usage & Resolution